Flagship Pioneering Elevates Four Senior Leaders

CAMBRIDGE, Mass., November 18, 2021 – Today Flagship Pioneering announced the promotions of four members of its Senior Leadership Team. Chuck Carelli, Chief Financial Officer, and Christine Heenan, Senior Partner and Chief Communications Officer, have been named Executive Partners. Stacie Rader has been named Senior Partner, Human Resources and Leda Trivinos has been named Senior Partner, Intellectual Property. Flagship Founder and CEO Noubar Afeyan shared the following remarks.

Chuck Carelli, Chief Financial Officer & Executive Partner

“Chuck has been an instrumental leader and steward of Flagship’s finance organization. He has been integral to Flagship’s growth journey playing a role in so many critical activities and milestones including every fund raise, company raise, and every merger. He is a valued partner and counsel to many within the Flagship ecosystem and to many of Flagship’s external partners. This promotion recognizes the leadership role he has played for Flagship broadly inclusive of his role as Chief Financial Officer.”

Christine Heenan, Chief Communications Officer & Executive Partner

“Since day one Christine has brought to bear her creativity and deep expertise in communications, public affairs, and institutional leadership to manage Flagship’s brand and reputation with excellence. Her leadership has created multiple high-impact opportunities to tell the story of Flagship and our companies, and to give a platform to voices across our ecosystem. She has quickly become a highly valued counselor to myself and other leaders at Flagship.”

Stacie Rader, Senior Partner, Human Resources

“I have had the privilege of working together with Stacie for nearly 30 years across several engagements and roles. Over the past 7 years, Stacie has been instrumental in driving our growth and helped build Flagship’s organization from 20 to over 220 team members today. She has brought experience, commitment and passion to the role, care for our employees, and deep knowledge of our business and history across the Flagship enterprise that has been of tremendous value.”

Leda Trivinos, Senior Partner, Intellectual Property

“Leda joined Flagship in 2015 and has shaped and built our Intellectual Property strategy and execution capability across the Flagship Enterprise. Her expertise and leadership have been critical to establishing an IP center of excellence for Flagship companies and she is frequently sought after for her wise counsel on a range of issues beyond IP. Leda has worked side-by-side with our Partners and origination teams to put in place thousands of robust IP filings and patents and this promotion is richly deserved.”

About Our Team Members

Chuck Carelli is Executive Partner and Chief Financial Officer at Flagship Pioneering. Chuck joined the firm in 2009 and brings more than 25 years of financial management, operations, and transaction experience to Flagship. His responsibilities include: managing the financial and legal aspects of firm operations at the fund and early stage portfolio company levels; business structure management; financing, liquidity, and M&A transaction execution; investor engagement at the fund and early stage portfolio company levels; and financial reporting, tax, treasury, and compliance oversight. Prior to joining Flagship, Chuck spent 13 years at three NASDAQ-listed Massachusetts-based biotech companies; most recently as CFO of Exact Sciences, and before that in senior financial roles at Alkermes and Creative BioMolecules. He began his career as a CPA in the Boston office of Deloitte. Chuck holds a B.A. in accounting from Assumption College.

Christine Heenan is Executive Partner and Chief Communications Officer at Flagship Pioneering overseeing communications, public affairs, brand management, and marketing for Flagship and its enterprise companies. She is the founder and former president of Clarendon Group, a consulting firm focused on social impact, communications, advocacy, and leadership voice. Previously, she served as Senior Vice President for Global Policy & Advocacy at The Rockefeller Foundation, where she led the Foundation’s policy, program influence, partnerships, and communications teams, as well as its regional teams in Asia, Africa, and Italy. From 2008 to 2015, Christine was Vice President of Public Affairs and Communications for Harvard University, overseeing its communications, government relations, and digital strategy teams in Cambridge, Boston, and Washington, DC. Christine began her career in business strategy consulting for Telesis and SJS – spinoffs of Boston Consulting Group – working on business process analysis, cost analysis, market strategy, and strategic planning for national and international corporations. Christine holds a B.S. in Journalism from Boston University and serves on the boards of the David Rockefeller Fund and the University of Rhode Island.

Stacie Rader is Senior Partner, Human Resources at Flagship Pioneering where she focuses the expanding functions and operations at the Flagship Pioneering Parent Company. Stacie joined Flagship in 2014 and has worked across flagship’s portfolio companies providing guidance on areas of human capital and HR operational issues including executive leadership, recruiting, compensation and corporate governance. Stacie was previously senior vice president, executive operations & human resources at BG Medicine and corporate director of worldwide employment and staffing for Applera Corporation (now Applied Biosystems) following the merger of Perkin Elmer and PerSeptive Biosystems. Stacie was responsible for all human resources functions at PerSeptive and was also a key member of corporate due diligence teams for several PerSeptive acquisitions. She was instrumental in the integration and assimilation process for the Perkin Elmer-PerSeptive merger. Stacie received a B.S. in business from Babson College.

Leda Trivinos is Senior Partner, Intellectual Property at Flagship Pioneering responsible for formulating and managing the intellectual property strategy for Flagship’s innovations and providing counsel across the portfolio. Previously, Leda was chief patent counsel for Momenta Pharmaceuticals Inc., a leader in the analysis and design of complex pharmaceutical products, where she led the company’s patent strategy to protect its technology and products, and to clear the way for successful product launches through patent enforcement and litigation. Prior to joining Momenta, she was assistant general counsel for intellectual property at Biogen Idec. She started her law career as an associate at Fish & Richardson PC, a global law firm specializing in intellectual property. Leda received her law degree from the University of California, Berkeley, School of Law and has a Ph.D. in cell and molecular biology from Northwestern University Medical School, where her research focused on motor proteins that drive intracellular transport. She was also a post-doctoral researcher in the lab of Suzanne Pfeffer, Ph.D. at Stanford University’s Biochemistry Department, focusing on Rab proteins involved in membrane traffic in human cells.

About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $200 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).